CTLA4 and melanoma: High percentages of proliferating (Ki‐67+) CD4+ T cells in responders of ICI therapy are consistent with Simpson et al.'s observation that CD4+ T cells were crucial mediators of the anti‐CTLA‐4 mechanism of action in a B16‐BL6 melanoma mouse model.6